HER2-positive Gastric Cancer Recruiting Phase 2 / 3 Trials for Margetuximab (DB14967)

IndicationStatusPhase
DBCOND0092590 (HER2-positive Gastric Cancer)Recruiting2 / 3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04082364Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer (MAHOGANY)Treatment